Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Non-Current Assets (2016 - 2025)

Syndax Pharmaceuticals has reported Other Non-Current Assets over the past 11 years, most recently at $102000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $102000.0 for Q4 2025, down 53.0% from a year ago — trailing twelve months through Dec 2025 was $102000.0 (down 53.0% YoY), and the annual figure for FY2025 was $102000.0, down 53.0%.
  • Other Non-Current Assets for Q4 2025 was $102000.0 at Syndax Pharmaceuticals, down from $217000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for SNDX hit a ceiling of $579000.0 in Q2 2023 and a floor of $102000.0 in Q4 2025.
  • Median Other Non-Current Assets over the past 5 years was $135500.0 (2021), compared with a mean of $183722.2.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 90.92% in 2021 and later soared 403.48% in 2023.
  • Syndax Pharmaceuticals' Other Non-Current Assets stood at $115000.0 in 2021, then changed by 0.0% to $115000.0 in 2022, then surged by 88.7% to $217000.0 in 2023, then changed by 0.0% to $217000.0 in 2024, then tumbled by 53.0% to $102000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $102000.0 (Q4 2025), $217000.0 (Q3 2025), and $217000.0 (Q2 2025) per Business Quant data.